drugset

drugset / Trial / NCT00509873

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

NCT00509873 ↗

Phase 3 Completed 578 enrolled Allergan

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

Timeline

Start: 2007-08
Primary completion: 2008-06
Completion: 2008-06

Publications

Heller W, Cruz M, Bhagat YR, De Leon JM, Felix C, Villanueva L, Hollander DA, Jensen H. Gatifloxacin 0.5% administered twice daily for the treatment of acute bacterial conjunctivitis in patients one year of age or older. J Ocul Pharmacol Ther. 2014 Dec;30(10):815-22. doi: 10.1089/jop.2014.0040.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gatifloxacin	Small molecule	0.5 %	Topical

Indications